Multiple sclerosis: active ingredient in sheep administration reduces relapses

Multiple sclerosis: active ingredient in sheep administration reduces relapses

We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

The Carstens Foundation reports on an Iranian study that examined the effects of a yarrow extract on the frequency of seizures and the occurrence of brain lesions in patients with multiple sclerosis (MS). Both can obviously be reduced by taking the plant extract.

The inflammatory event that occurs in the relapsing phase of patients with MS leads to lesions in the brain or spinal cord area. By default, patients are treated with immunomodulating therapy to avoid further neurological damage. This therapy does not always lead to success.

Iranian scientists have now investigated whether herbal therapy using an extract from the yarrow (Achillea millefolium) can increase its effectiveness in parallel with standard therapy. The study ran over a year. For the study, 75 patients with remitting multiple sclerosis were randomly divided into three groups. The subjects in the first group received 250 mg / day Achillea extract, those in the second group 500 mg / day Achillea extract and the third group placebo.

The Achillea extract contained both 0.28 mg / g luteolin and 1.58 mg / g apigenin.

On average, the subjects of the two verum groups suffered significantly less from relapses. The time to the first relapse was longer in the verum groups than in the placebo group. The higher dose extract significantly reduced the risk of recurrence and the volume of the lesions occurring compared to the lower dose and the placebo preparation. In the results of the neuropsychological examinations, the Achillea extracts also performed better than placebo. This also applied to cognitive performance and the management of executive functions (e.g. strategic action planning). In addition, the subjects in the verum groups suffered less from depressive moods. Source. Carstens Foundation

Author and source information

Video: Relapsing Remitting Multiple Sclerosis Treatment (July 2022).


  1. Everardo

    You are not right. Write in PM, we will talk.

  2. Cheval

    Wacker, it seems to me, it is a magnificent phrase

  3. Adio

    We know the measure, but will you drink it? Done, master! - What's ready? - BROKEN !!!

  4. Migrel

    What quite good topic

  5. Dao

    I congratulate, very good idea

  6. Zululkree

    It agree, rather useful message

  7. Domevlo

    I will not begin to speak on this theme.

Write a message